Get the Stockscreener App
1.00
2.91%
-0.03
After Hours:
1.00
Ocugen Inc stock is traded at $1.00, with a volume of 5.02M.
It is down -2.91% in the last 24 hours and down -24.81% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.03
Open:
$1.03
24h Volume:
5.02M
Relative Volume:
0.85
Market Cap:
$339.11M
Revenue:
$4.47M
Net Income/Loss:
$-71.67M
P/E Ratio:
-4.3141
EPS:
-0.2318
Net Cash Flow:
$-59.58M
1W Performance:
+0.00%
1M Performance:
-24.81%
6M Performance:
-44.13%
1Y Performance:
-40.48%
1-Day Range:
$1.00
$1.05
1-Week Range:
$1.00
$1.10
52-Week Range:
$0.97
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.00 | 345.89M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
506.74 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
734.81 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
188.94 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
936.00 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.89 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
3rd Circ. Topples Materiality Rule For Securities Suits - Law360
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen, Inc. (OCGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ocugen Row Revived as Third Cir. Dumps Investor Materiality Rule - Bloomberg Law News
A gene therapy poster will report three-year vision benefits across mutations - Stock Titan
Enterprise value to EBIT forward of Ocugen Inc – HAN:2H51 - TradingView
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen Inc Earnings and Revenue – HAN:2H51 - TradingView
Ocugen Inc Revenue Breakdown – HAN:2H51 - TradingView
Analysts Conflicted on These Healthcare Names: Ocugen (OCGN), Aveanna Healthcare Holdings (AVAH) and Universal Health (UHS) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN) - The Globe and Mail
Ocugen to Participate in Upcoming October Investor and Industry Conferences - GlobeNewswire
H.C. Wainwright raises Ocugen stock price target on Bahamas approval By Investing.com - Investing.com Nigeria
What's Behind Ocugen's (NASDAQ:OCGN) Big Moment in Healthcare Stocks? - kalkinemedia.com
H.C. Wainwright raises Ocugen stock price target on Bahamas approval - Investing.com
Ocugen's Retina Data Impress, but a 250 Million Share Vote Still Holds the Reins - AD HOC NEWS
Ocugen's Island Approval Arrives as a 250 Million Share Decision Waits in the Wings - AD HOC NEWS
Ocugen's Bahamian Green Light Meets a Shareholder Reckoning - AD HOC NEWS
Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen receives provisional approval for gene therapy in Bahamas By Investing.com - Investing.com Nigeria
Ocugen Wins Bahamas Priority Path for OCU400 Gene Therapy - MyChesCo
Ocugen Receives OCU400 Priority Designation in Bahamas - grafa.com
Why Is OCGN Stock Rising Today? - stocktwits.com
Ocugen Gets Provisional Approval for OCU400 in Bahamas - marketscreener.com
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days - Yahoo Finance
Ocugen's 32% Lesion Slowdown Meets a Balance Sheet That Won't Wait - AD HOC NEWS
OCGN Looks 22.0% Overvalued on GF Value™ - GuruFocus
Ocugen receives provisional approval for gene therapy in Bahamas - Investing.com
Ocugen Announces Expanded Access Program for OCU400 in Retinitis Pigmentosa Following LARTA Provisional Approval - quiverquant.com
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa - Ocugen, Inc.
Ocugen Stockholders Approve Meeting Adjournment for Share Increase - The Globe and Mail
Ocugen (OCGN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Ocugen stockholders approve adjournment of special meeting for share increase vote - Investing.com Nigeria
Why Is Ocugen (NASDAQ:OCGN) Back in Focus as Wall Street Balances Growth and Defensive Demand? - Kalkine Media
Form 8K Ocugen, Inc For: 23 September By Investing.com - Investing.com Australia
Form 8K Ocugen, Inc For: 23 September - Investing.com India
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $9.5 - Moomoo
OCGN: Proposal to increase authorized shares delayed due to insufficient votes; adjournment approved - TradingView
OCGN: Proposal to increase authorized shares stalled; adjourned meeting set for further voting - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Did OCGN Stock Rise Today? - Stocktwits
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances - TradingView
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Australia
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 - investing.com
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical (NASDAQ:OCGN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Ocugen to Share Ophthalmic Gene Therapy Progress - TipRanks
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ocugen Inc Stock (OCGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Musunuri Shankar | Chief Executive Officer |
Sep 09 '26 |
Sale |
1.12 |
57,264 |
64,136 |
1,088,035 |
1.48%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):